{"entity":{"id":"nct06682572","kind":"trial","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","aka":[],"tldr":"A phase 2 trial of Avutometinib (VS-6766) + Defactinib (VS-6063) in ovarian cancer, run by Verastem, Inc., active and no longer recruiting.","summary":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients is a phase 2 interventional study registered as NCT06682572 by Verastem, Inc., with 16 participants enrolled, started 2024-10-30 and due to reach its primary completion in 2025-12. Interventions recorded: Avutometinib (VS-6766) + Defactinib (VS-6063).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06682572","url":"https://clinicaltrials.gov/study/NCT06682572"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06682572","phase":"2","setting":"A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Japanese Patients","sponsor":"Verastem, Inc.","enrolled":16,"outcomes":[]},"route":"/trials/nct06682572/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}]}}